In addition, whereas responses have been observed to tarlatamab in patients with SCLC and no DLL3 IHC expression,6 patients with extrapulmonary NECs treated with obrixtamig appear to require >50% tumor cell (DLL3-high) expression for response37—notably, 32 of 78 (41%) GEP NECs and 10 of 52 (19%) G3 PanNETs in our data set met this criteria for DLL3-high expression. Here, DLL3 is linked to small cell lung carcinoma.